Recent updates in therapeutic approach using tolvaptan for autosomal dominant polycystic kidney disease

As a genetic disease, there has been a long-standing effort to identify therapeutic options for autosomal dominant polycystic kidney disease (ADPKD). Following the development of tolvaptan, a vasopressin 2 receptor antagonist, the treatment strategy for ADPKD patients with rapid disease progression...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Yaerim, Han, Seungyeup
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association of Internal Medicine 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175869/
https://www.ncbi.nlm.nih.gov/pubmed/37089056
http://dx.doi.org/10.3904/kjim.2022.376

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175869/
https://www.ncbi.nlm.nih.gov/pubmed/37089056
http://dx.doi.org/10.3904/kjim.2022.376

Ejemplares similares